Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Clinical trial NCT02273739 · COMPLETED
Trial details
- NCT number
- NCT02273739
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-08
- Primary completion
- 2016-06-03
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.